OnQ Neuro

by CorTechs Labs  · Based in United States → — AI-powered quantitative MRI analysis for brain tumors.
Neurosurgery Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing
Regulatory Status Disclosed

Overview

OnQ Neuro is a fully automated post-processing medical device software developed by CorTechs Labs. It is designed to assist radiologists, oncologists, and other clinicians in the analysis and interpretation of neurological MR images. The software performs automatic segmentation and volumetric quantification of brain tumors, which are known or confirmed to be pathologically diagnosed cancer. Additionally, OnQ Neuro provides automatic fusion of derived parametric maps with anatomical MRI data and enables the comparison of derived image metrics from multiple time-points. Utilizing deep learning, OnQ Neuro aims to enhance the accuracy and efficiency of brain tumor evaluation. It is intended for use in the adult population only, providing quantitative reports and derived image data sets as complementary information in case review.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fully automated post-processing medical device software
  • Automatic segmentation and volumetric quantification of brain tumors
  • Analysis and interpretation of neurological MR images
  • Automatic fusion of derived parametric maps with anatomical MRI data
  • Comparison of derived image metrics from multiple time-points
  • Utilizes deep learning for tumor segmentation and quantification
  • Supports DICOM images
  • Generates quantitative reports
  • Intended for adult population only
  • Output of DICOM-compatible objects (RT-Struct)

Use Cases

  • Assisting radiologists, oncologists, and clinicians with neurological MR image analysis
  • Evaluating brain tumors (known/confirmed pathologically diagnosed cancer)
  • Monitoring disease progression through comparison of multiple time-points
  • Discriminating tumor from non-tumor tissue
  • Measuring tumor progression and treatment response
  • Predicting clinical outcomes

What Physicians Need to Know

Brain MRI Analysis
OnQ Neuro is a fully automated post-processing medical device software designed for analyzing and evaluating neurological MR image data. It provides automatic segmentation, quantification, and reporting of derived image metrics.
Brain Tumor Focus
The software is specifically intended for use on brain tumors that are known or confirmed to be pathologically diagnosed cancer. It offers objective tumor volumetrics for both high-grade and low-grade gliomas.
Longitudinal Tracking
OnQ Neuro is intended for the comparison of derived image metrics from multiple time-points, enabling longitudinal volumetric assessments pre- and post-operatively for brain tumor patients.
Automated Segmentation & Quantification
The tool performs automatic segmentation and volumetric quantification of brain tumors, as well as automatic post-acquisition analysis of diffusion-weighted MRI data and optional automated fusion of derived image data with anatomical MR images.
DICOM Output
OnQ Neuro output is provided in standard DICOM format as image series and reports, which can be displayed on most third-party commercial DICOM workstations.
Physician Tip

OnQ Neuro serves as a valuable complementary tool for radiologists, oncologists, and other clinicians by providing objective, quantitative data from neurological MR images, particularly for brain tumor analysis and tracking. While the software offers automated insights, the physician retains the ultimate responsibility for making the final diagnosis and treatment decisions. Its ability to track changes over time can enhance monitoring of disease progression and treatment efficacy.

OnQ Neuro is a standalone medical device software package designed for installation in the cloud or within a hospital's IT infrastructure (server or PC-based workstation). Once configured, it automatically processes DICOM images sent from an MRI scanner or PACS and outputs DICOM data to a network destination, operating without the need for a user interface after installation.

Details

Category Neurology AI, Oncology AI
Pricing Contact vendor for pricing
DeploymentCloud-based
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated

OnQ Neuro received FDA 510(k) clearance (K210831) on November 19, 2021. It is a fully automated post-processing medical device software intended for analyzing and evaluating neurological MR image data, providing automatic segmentation, quantification, and reporting of derived image metrics for brain tumors.
Integrations
EHR Not specified
Specialties Neurosurgery, Oncology, Radiology

What the Web Says

OnQ Neuro, developed by Cortechs.ai, is an FDA 510k-cleared AI solution designed for automated post-processing and analysis of neurological MRI data, specifically for evaluating brain tumors. It provides automatic segmentation, quantification, and reporting of derived image metrics, as well as fusion of parametric maps with anatomical MRI data. The software is intended to be used by trained personnel in clinical practice as complementary information for diagnosis and treatment decisions. While there are positive reviews for Cortechs.ai's other products like NeuroQuant, specific detailed reviews for OnQ Neuro from independent tech reviewers, G2, Capterra, or Reddit are limited. However, general sentiment from physicians and case studies suggests a positive outlook on its capabilities.

Overall: Positive

Strengths

  • Automated, image-based 3D volumetric analysis of brain tumors.
  • FDA 510k-cleared medical device software.
  • Provides precise and objective measurements, addressing the limitations of manual 2D measurements.
  • Consistent segmentation performance across various scanner manufacturers, field strengths, tumor types, and patient sexes.
  • Outputs in standard DICOM format, compatible with most third-party commercial DICOM workstations.
  • Can track tumor changes over multiple time points, aiding in longitudinal follow-up.

Limitations

  • Limited independent reviews specifically for OnQ Neuro on platforms like G2, Capterra, or Reddit.
  • Requires trained technical personnel for installation and trained personnel for use.
  • Intended for use on adult populations only.
  • Quantitative reports and derived image data sets are intended as complementary information, not a replacement for physician's final diagnosis.

Based on reviews from: CorTechs Labs, Inc., Cortechs.ai, Reddit, YouTube, Capterra

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate OnQ Neuro

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Cortechs.ai
Quantitative MRI and prostate cancer - Cortechs.ai
Cortechs.ai announced at RSNA 2021 the introduction of OnQ Neuro, an FDA-cleared device for automated brain tumor segmentation using Restriction Spectrum Imaging (RSI) technology. The company also showcased NeuroQuant, NeuroQuant MS, and OnQ Prostate.
2021-11
FDA
CorTechs Labs, Inc. 510(k) Premarket Notification
The FDA issued a 510(k) clearance for CorTechs' OnQ Neuro on November 19, 2021. This document details the device's intended use for automated post-processing of neurological MR image data for segmentation, quantification, and reporting of derived image metrics for brain tumors.
2021-11
RSNA 2025 Daily Bulletin
Looking Beyond the Image to Imagine a Better World for Everyone - RSNA 2025 Daily Bulletin
The RSNA 2022 Daily Bulletin highlighted OnQ Neuro as a tool for precision tracking of brain tumor volumes and quantitative mapping over time, leveraging Restriction Spectrum Imaging (RSI). It was presented as an FDA 510(k) cleared solution for timely and accurate diagnoses.
2022-11
RSNA 2025 Daily Bulletin
Welcome to RSNA 2022 - RSNA 2025 Daily Bulletin
Cortechs.ai showcased OnQ Neuro at RSNA 2022, emphasizing its capabilities in precision tracking of brain tumor volumes and quantitative mapping over time using Restriction Spectrum Imaging (RSI).
2022-11
Cortechs.ai
NeuroQuant 4.0: Improved segmentation - Cortechs.ai
Cortechs.ai announced NeuroQuant 4.0 with improved segmentation features, noting that their FDA-cleared product, OnQ Neuro, also utilizes deep learning for segmenting brain tumors by subregion.
2023-02
Cortechs.ai
NeuroQuantu00ae Brain Tumor: Case Study - Cortechs.ai
This case study from Cortechs.ai highlights the value of NeuroQuantu00ae Brain Tumor, an FDA 510k-cleared AI solution, in providing automated, image-based 3D volumetric analyses of diagnosed brain tumors. The article references OnQ Neuro as a related product.
2023-03
ResearchGate
CorTechs' FDA-pending OnQu2122 Neuro utilizes deep learning for tumor... - ResearchGate
A scientific diagram on ResearchGate illustrates how CorTechs' FDA-pending OnQ Neuro utilizes deep learning for tumor segmentation and quantification on MRI, showcasing its application in segmenting glioblastoma multiforme.
2021-05
Newswire
Cortechs.ai Appoints New Chief Financial Officer | Newswire
Cortechs.ai announced the appointment of its new CFO and mentioned the upcoming commercial launch of its recently FDA-cleared neuro-oncology software, OnQ Neuro, in late 2022, continuing its pioneering work in advanced cancer detection.
2022-06

Videos

Product demos, reviews, and walkthroughs for OnQ Neuro.

View all on YouTube

Frequently Asked Questions

OnQ Neuro is a fully automated post-processing medical device software designed to assist radiologists, oncologists, and other clinicians in analyzing and interpreting neurological MR images. It performs automatic segmentation and volumetric quantification of brain tumors that are known or confirmed to be pathologically diagnosed cancer in adult patients. The software also facilitates the comparison of derived image metrics from multiple time-points to track changes.
Yes, OnQ Neuro is FDA 510(k) cleared as a Class II medical device under product code QIH (K210831). The premarket notification demonstrates its compliance with international and FDA-recognized consensus standards and guidance documents.
OnQ Neuro is intended for use only on brain tumors that are known or confirmed to be pathologically diagnosed cancer and is restricted to the adult population. It exclusively supports MR scans and does not specifically incorporate oncology response criteria. Physicians maintain ultimate responsibility for final diagnosis and treatment decisions, as AI tools are dependent on the quality of their training data.
While OnQ Neuro specifically focuses on automated segmentation and volumetric quantification of brain tumors, other AI solutions like NeuroQuant (from the same developer, CorTechs.ai) offer broader neuroimaging analyses for conditions such as Alzheimer's, epilepsy, and multiple sclerosis. Competitors in the general neuroimaging AI space include Mirada XD, IntelliSpace Portal, BrainSightAI, and Quantib Brain, which may offer different specialized applications or broader visualization platforms.
Specific pricing or licensing models for OnQ Neuro are not publicly disclosed in the available information. Typically, medical device software like OnQ Neuro involves direct consultation with the vendor, CorTechs Labs, Inc., to obtain a price estimate based on institutional needs and deployment models (e.g., cloud or on-premise).
OnQ Neuro is specifically designed to assist in the analysis and evaluation of neurological MR image data for brain tumors that are known or confirmed to be pathologically diagnosed cancer. It provides automatic segmentation, quantification, and reporting of derived image metrics for these specific cases.
OnQ Neuro's software verification and validation activities demonstrated that it meets defined functionality requirements and performance claims. Its automatic segmentation performance is evaluated by comparing software-derived segmentations to expert-labeled segmentations of brain tumors, with acceptance criteria set for consistency with expert rater manual segmentation performance. The software is intended to be used by trained personnel and provides quantitative reports as complementary information.

Compare OnQ Neuro

VS
NeuroQuant vs OnQ Neuro
Neurology AI Adjacent · 75/100
NeuroQuant offers broad brain MRI volumetric analysis for neurodegenerative diseases, trauma, and general lesions, including comparisons to normative data. OnQ Neuro, while also from CorTechs Labs, specializes in…

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Paid
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
Per-test pricing
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

More from CorTechs Labs

LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
NeuroQuant
CorTechs Labs
Neurology AI
NeuroQuant by CorTechs Labs is an FDA-cleared, AI-powered software for automated brain MRI segmentation and volumetric analysis, aiding in the diagnosis and monitoring of neurodegenerative diseases, brain trauma, and tumors.
Subscription

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.